Sonographic Assessment of Uterine Biometry for the Diagnosis of Diffuse Adenomyosis in a Tertiary Outpatient Clinic

Diego Raimondo 1, Lucia Lazzeri 2, Antonio Raffone 1,3,* , Matteo Giorgi 2, Benedetta Orsini 1,3, Ludovica Verrelli 1,3, Jacopo Lenzi 4,6, Antonino Travaglino 5,8, Lucia De Meis 1, Antonio Mollo 7, Errico Zupi 2, Renato Seracchioli 1,3 and Paolo Casadio 1

1 Division of Gynecology and Human Reproduction Physiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
2 Department of Molecular and Developmental Medicine, Obstetrics and Gynecological Clinic, University of Siena, 53100 Siena, Italy
3 Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy
4 Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy
5 Gynecopathology and Breast Pathology Unit, Department of Woman and Child’s Health Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
6 Department of Advanced Biomedical Sciences, University of Naples “Federico II”, 80138 Naples, Italy
7 Gynecology and Obstetrics Unit, Department of Medicine, Surgery and Dentistry “Schola Medica Salernitana”, University of Salerno, 84084 Baronissi, Italy
* Correspondence: anton.raffone@gmail.com or antonio.raffone2@unibo.it

Abstract: Background: to compare several uterine biometric parameters at transvaginal ultrasound (TVUS) between adenomyosis and non-adenomyosis uteri and evaluate their role for the diagnosis of diffuse adenomyosis. Methods: prospective observational study conducted between the 1 February 2022 and the 30 April 2022. In this case, 56 patients with TVUS diagnosis of adenomyosis were included. A 1:1 ratio age and parity-matched group of non-adenomyosis patients was selected. We compared sonographic uterine biometric parameters (longitudinal (LD), anteroposterior (APD) and transverse (TD) diameters, volume, simple and complex diameter ratios) and investigated their diagnostic performance. Results: all sonographic parameters were significantly different between the study groups, except for TD/(LD+APD). Optimal cut-off values of APD and LD/APD showed the best sensitivity and specificity. APD diameter equal or superior to 39.5 mm (95% CI, 36.2–42.8) had sensitivity of 0.70 (95% CI, 0.57–0.80), specificity of 0.71 (95% CI, 0.59–0.82) and accuracy of 0.75 (95% CI, 0.66–0.84). LD/APD equal or inferior to 2.05 (95% CI, 1.96–2.13) showed sensitivity and specificity of 0.70 (95% CI, 0.57–0.80) each and accuracy of 0.72 (95% CI, 0.62–0.81). Conclusions: several biometric uterine parameters at TVUS in fertile-aged women were statistically different between adenomyosis and non-adenomyosis uteri, though their optimal cut-off values showed low accuracy in diagnosing adenomyosis.

Keywords: adenomyosis; biometry; diagnosis; globular uterus; ultrasonography; ultrasound

1. Introduction

Adenomyosis is a benign gynecological disease described by the presence of endometrial glands and stroma within the myometrium, as well as reactive hyperplasia and hypertrophy of the muscular layer [1]. Adenomyosis can be focal or more frequently diffuse and may involve junctional zone and/or outer myometrium [2–4]. When symptomatic, it can be the cause of abnormal uterine bleeding, pelvic pain and subfertility [2–5].

The reported prevalence of adenomyosis at pathological evaluation varies between studies from 21% to 36% according to different patients’ inclusion (e.g., age, symptoms, co-existent endometriosis) and histological criteria adopted [6–8]. However, because only a
small, selected group of women undergo hysterectomy, the real prevalence of adenomyosis is likely underestimated, particularly in fertile-age women who have not accomplished childbearing and/or in patients with less advanced disease [9].

Therefore, non-invasive diagnosis of adenomyosis is clinically needed to also manage patients with actual or future desire of pregnancy. Transvaginal ultrasound (TVUS) should be considered the primary imaging tool in experienced hands, since it is an accurate, low cost and easily accessible method [10–12].

The aim to provide a standardized terminology for describing ultrasound images of normal and pathological myometrium, minimizing inter-operator variability, has been realized with the Morphological Uterus Sonographic Assessment (MUSA) consensus [2], which provided a list of sonographic features associated with adenomyosis [3]. Noteworthy, the importance of each item or their combinations for the TVUS diagnosis of adenomyosis has yet to be clearly defined. Among sonographic parameters, globular uterus is a qualitative assessment defined as a uterine configuration characterized by a rounded fundus and a more spherical shape [13,14]. Available studies evaluating its performance for adenomyosis diagnosis showed controversial results [10,11,15–18].

To the best of our knowledge, there are poor data and controversial results on diagnostic performance of some quantitative biometrical parameters that can differentiate adenomyosis uteri from non-adenomyosis ones [19,20].

The aim of this study is to compare uterine biometric parameters at TVUS between uteri with diffuse adenomyosis and uteri without adenomyosis and evaluate their potential role for the diagnosis of diffuse adenomyosis.

2. Materials and Methods

2.1. Study Protocol and Selection Criteria

The study followed an a priori defined study protocol and was designed as an observational, prospective, case-control study. The whole study was reported following the STROBE guidelines and checklist [21].

We enrolled all consecutive patients referring to our tertiary outpatient clinic for gynecological ultrasound between the 1 February 2022 and the 30 April 2022. We a priori defined as exclusion criteria: age less than 18 years, virgo status, postmenopausal status, ongoing or recent (less than 6 months) pregnancy, suspicion of gynecological malignancy, uterine malformations, previous surgery for adenomyosis or fibroids, focal adenomyosis lesions larger than 1 cm (focal adenomyosis/adenomyoma), and myomas larger than 1 cm.

2.2. Case and Control Groups

Cases group consisted of eligible women with sonographic criteria suggestive of adenomyosis according to the MUSA consensus [2,3] and presence of question mark sign [6].

Controls group was selected through a 1:1 ratio matching with cases for potential confounding factors (i.e., age, parity and hormonal therapy) and included consecutive eligible patients with no or one sonographic criteria suggestive of adenomyosis at routine evaluation in our Hospital during the study period.

The two study groups (adenomyosis uteri versus non adenomyosis uteri) were compared in terms of baseline and sonographic variables.

2.3. Study Outcomes

Primary outcomes were the comparisons of sonographic biometric parameters (absolute uterine diameters and simple and complex diameter ratios) between the two study groups.

Secondary outcomes included the diagnostic performance of optimal cut-off values of the investigated biometric parameters in diagnosing diffuse adenomyosis.
2.4. Patient Assessment and Ultrasound Details

Women received an accurate anamnestic evaluation, gynecological bimanual palpation, and 2D-3D transvaginal ultrasound scan.

Baseline characteristics [e.g., age, body mass index (BMI), parity, hormonal therapy ≥ 3 months before study, previous surgery for endometriosis, moderate-to-severe pain symptoms defined as numerical rating scale equal or superior to 5, and heavy menstrual bleeding referred to as pictorial blood loss analysis chart ≥ 100] were obtained for all patients.

All TVUS examinations were conducted by highly trained expert sonographers using a 2-, 3-dimensional micro-convex endocavity transducer with a frequency range of 4 to 9 MHz (Voluson E8; GE Healthcare, Zipf, Austria). Ultrasound examinations were performed in order to detect the presence of any sonographic features suggestive of adenomyosis according to the MUSA consensus [2,3] and of question mark sign [6]. Sonographic features suggestive of adenomyosis according to the MUSA consensus include the presence of globular uterus appearance, asymmetrical thickening, hypoechogenic myometrial cysts, hyperechoic islands, fan-shaped shadowing, echogenic subendometrial lines and buds, translesional vascularity, irregular or interrupted junctional zone at 2D and 3D evaluations [18,22,23]. Adenomyosis was diagnosed when two or more of the above-mentioned sonographic criteria were present [15,24].

Uterine longitudinal (LD), anteroposterior (APD) and transverse (TD) diameters and volume were acquired at TVUS for all patients, and diameter sums, and simple and complex diameter ratios were calculated. In particular, assessed diameter sums were APD+TD and LD+APD, simple diameter ratios were LD/APD, LD/TD, and APD/TD, and complex diameter ratios were LD/(APD+TD) and TD/(LD+APD). LD was measured as the entire uterine length: the sum of the uterine corpus (from the fundal serosal surface to the internal os) and the cervix length. The longest anteroposterior diameter was measured in the sagittal plane and the longest transverse diameter in the transverse plane (Figure 1). Volume of the uterus was calculated with the following formula: uterine corpus × APD × TD × 0.52.

Figure 1. Standardized uterine measurement according to the MUSA consensus [2]. Longitudinal diameter (LD) is the entire uterine length measured as the sum of uterine corpus (Ut-L) and cervix length (Ut-Cervix L). Anteroposterior diameter (APD) and transverse diameter (TD) are measured in the sagittal (Ut-H) and transverse plane (Ut-W), respectively.

2.5. Statistical Analysis

Categorical variables were summarized as frequencies and percentages, while numerical variables were summarized as mean ± standard deviation (SD) and median [interquartile range]. Baseline characteristics in the two study groups were compared with the Chi-squared test, Fisher’s exact test and t-test or Wilcoxon rank-sum (Mann–Whitney) test, where appropriate.

In order to investigate the presence of systematic differences in the biometric measurements of the uterus between the two study groups we performed the Wilcoxon rank-sum
(Mann–Whitney) test. The measures that exhibited a significant association with the diagnosis of adenomyosis at Mann–Whitney test were further evaluated with nonparametric receiver operating characteristic (ROC) analysis. More specifically, the optimal cutoff value was determined using the Liu method, which maximizes the product of the sensitivity and specificity.

Diagnostic accuracy was a priori categorized as null for AUC ≤ 0.5, low for 0.5 < AUC ≤ 0.75, moderate for 0.75 < AUC ≤ 0.9, high for 0.9 < AUC < 0.97, and very high for AUC ≥ 0.97, as previously reported [25].

All analyses were carried out using Stata software, version 17 (StataCorp, 2021, Stata Statistical Software: Release 17, College Station, TX, USA: StataCorp LP). All tests were two-sided, and the significance level was set at 0.05.

2.6. Ethical Statement and Informed Consent

The study protocol received approval by the local Ethics Committee (114/2022/Oss/AOUBo). All patients signed an informed consent before entering the study, and all data were anonymized.

3. Results

During the study period, we enrolled 56 women with sonographic diagnosis of diffuse adenomyosis as cases, and 56 matched patients without sonographic diagnosis of diffuse adenomyosis as controls.

Patients' characteristics are presented in Table 1. The mean (±SD) age and BMI (±SD) of the entire study population were 37.6 (±7.7) and 24.0 (±3.3), respectively. In this case, 66 patients (59%) assumed hormonal therapy before entering the study. Most of the patients (68%) were nulliparous.

Table 1. Baseline characteristics of the entire study population and of the two study groups.

| Characteristic                      | All (n = 112) | Adenomyosis (n = 56) | No (n = 56) | p-Value |
|-------------------------------------|--------------|----------------------|-------------|---------|
| Age, y (±SD)                        | 37.6 ± 7.7   | 37.5 ± 7.7           | 37.7 ± 7.7  | 0.913   |
| BMI (±SD)                           | 24.0 ± 3.3   | 23.6 ± 3.3           | 24.2 ± 3.4  | 0.098   |
| Age group, y                        |              |                      |             | 0.996   |
| ≤25                                 | 9 (8%)       | 5 (9%)               | 4 (7%)      |         |
| 26–30                               | 15 (13%)     | 7 (13%)              | 8 (14%)     |         |
| 31–35                               | 12 (11%)     | 6 (11%)              | 6 (11%)     |         |
| 36–40                               | 34 (30%)     | 16 (29%)             | 18 (32%)    |         |
| 41–45                               | 24 (21%)     | 13 (23%)             | 11 (20%)    |         |
| >45                                 | 18 (16%)     | 9 (16%)              | 9 (16%)     |         |
| Parity                              |              |                      |             | 0.555   |
| 0                                   | 76 (68%)     | 38 (68%)             | 38 (68%)    |         |
| 1                                   | 25 (22%)     | 11 (20%)             | 14 (25%)    |         |
| 2                                   | 11 (10%)     | 7 (12%)              | 4 (7%)      |         |
| Hormonal therapy for ≥3 months before study | | | | 0.157 |
| None                                | 46 (41%)     | 23 (41%)             | 23 (41%)    |         |
| Progestin                           | 34 (30%)     | 21 (38%)             | 13 (23%)    |         |
| Intrauterine device                 | 17 (15%)     | 8 (14%)              | 9 (16%)     |         |
| Estrogen/progesterin                | 15 (13%)     | 4 (7%)               | 11 (20%)    |         |
| Previous surgery for endometriosis | 42 (38%)     | 20 (41%)             | 22 (21%)    | <0.001  |
| Pain symptoms (NRS ≥ 5)             |              |                      |             |         |
| Dysmenorrhea                        | 14 (13%)     | 9 (16%)              | 5 (9%)      | 0.253   |
| Dyspareunia                         | 15 (13%)     | 11 (20%)             | 4 (7%)      | 0.052   |
| Ovulation pain                      | 4 (4%)       | 3 (5%)               | 1 (2%)      | 0.618   |
| Chronic pelvic pain                 | 7 (6%)       | 6 (11%)              | 1 (2%)      | 0.113   |
| Dysuria                             | 1 (1%)       | 0 (0%)               | 1 (2%)      | 1.000   |
| Dyschezia                           | 3 (3%)       | 3 (5%)               | 0 (0%)      | 0.243   |
| Heavy menstrual bleeding (PBAC ≥ 100) | 9 (8%)     | 8 (14%)              | 1 (2%)      | 0.016   |

*a p-value ≤ 0.05. All characteristics were expressed as number (percentage). Abbreviations: y, years; NRS, numerical rating scale; BMI: body mass index; PBAC: Pictorial Blood Assessment Chart.
As reported in Table 2, all sonographic features suggestive of adenomyosis were significantly different between normal and adenomyosis uteri.

Table 2. Ultrasonographic characteristics of the entire study population and of the two study groups.

| Characteristic                          | All  (n = 112) | Adenomyosis | p-Value |
|----------------------------------------|----------------|-------------|---------|
|                                        |                | Yes (n = 56) | No (n = 56) |         |
| Globular uterus                        | 46 (41%)       | 41 (73%)    | 5 (9%)   | <0.001  |
| Fan-shaped shadows                     | 38 (34%)       | 37 (66%)    | 1 (2%)   | <0.001  |
| Hyperechogenic islands                 | 36 (32%)       | 36 (64%)    | 0 (0%)   | <0.001  |
| JZ interruption/irregularities         | 36 (32%)       | 30 (54%)    | 6 (11%)  | <0.001  |
| Anechoic myometrial cysts              | 35 (31%)       | 34 (61%)    | 1 (2%)   | <0.001  |
| Trans-lesional vascularity             | 33 (29%)       | 33 (59%)    | 0 (0%)   | <0.001  |
| Echogenic sub-endometrial lines and buds | 32 (29%)  | 32 (57%)    | 0 (0%)   | <0.001  |
| Asymmetry of the uterine walls         | 52 (46%)       | 45 (80%)    | 7 (13%)  | <0.001  |
| QM sign                                | 18 (16%)       | 18 (32%)    | 0 (0%)   | <0.001  |

*p-value ≤0.05. Notes: Values are n (%), or mean ± standard deviation and median [interquartile range]. Abbreviations: JZ: junctional zone; QM: question mark.

All uterine diameters and uterine volume were significantly different between the two groups (Figure 2).

Figure 2. Box plots showing absolute uterine diameters and volume of the uterus, by presence or absence of adenomyosis. *p-value ≤ 0.05. Notes: The box represents the interquartile range (IQR), i.e., the distance between the 1st and the 3rd quartile (Q1, Q3); the bar and diamond inside the box represent the median and the mean, respectively; the whiskers represent the lower and upper adjacent values, i.e., the lowest observation ≥ Q1 – 1.5 × IQR and the largest observation ≤ Q3 + 1.5 × IQR; the circles represent the individual values observed outside the whiskers (outliers).

Similarly, simple and complex diameter ratios were statistically different between the two groups, except for TD/(LD+APD) (Figures 3 and 4).
**Figure 3.** Box plots showing simple diameter ratios of the uterus, by presence or absence of adenomyosis. *p*-value ≤ 0.05. Notes: The box represents the interquartile range (IQR), i.e., the distance between the 1st and the 3rd quartile (Q1, Q3); the bar and diamond inside the box represent the median and the mean, respectively; the whiskers represent the lower and upper adjacent values; i.e., the lowest observation ≥ Q1 – 1.5 × IQR and the largest observation ≤ Q3 + 1.5 × IQR; the circles represent the individual values observed outside the whiskers (outliers). Abbreviations: LD, longitudinal diameter; APD, antero-posterior diameter; TD, transverse diameter.

**Figure 4.** Box plots showing diameter sum and complex diameter ratios of the uterus, by presence or absence of adenomyosis. *p*-value ≤ 0.05. Notes: The box represents the interquartile range (IQR), i.e., the distance between the 1st and the 3rd quartile (Q1, Q3); the bar and diamond inside the box represent the median and the mean, respectively; the whiskers represent the lower and upper adjacent values; i.e., the lowest observation ≥ Q1 – 1.5 × IQR and the largest observation ≤ Q3 + 1.5 × IQR; the circles represent the individual values observed outside the whiskers (outliers). Abbreviations: LD, longitudinal diameter; APD, antero-posterior diameter; TD, transverse diameter.

As illustrated in Table 3, optimal cutoff of each biometric parameter demonstrated a low discriminative value for the diagnosis of adenomyosis.
Table 3. Results of nonparametric receiver operating characteristic (ROC) analysis conducted on the absolute uterine diameters, simple and complex diameter ratios and volume of the uterus to discriminate adenomyosis.

| Measurement            | Optimal Cutoff | Sensitivity at Cutoff | Specificity at Cutoff | AUC       |
|------------------------|----------------|-----------------------|-----------------------|-----------|
|                        | Est. (95% CI)  | Est. (95% CI)         | Est. (95% CI)         | Est. (95% CI) |
| LD, cm                 | 78.5 (73.6, 83.4) | 0.64 (0.51, 0.76)     | 0.66 (0.53, 0.77)     | 0.67 (0.57, 0.77) |
| APD, cm                | 39.5 (36.2, 42.8) | 0.70 (0.57, 0.80)     | 0.71 (0.59, 0.82)     | 0.75 (0.66, 0.84) |
| TD, cm                 | 52.5 (46.6, 58.4) | 0.50 (0.37, 0.63)     | 0.82 (0.70, 0.90)     | 0.70 (0.60, 0.80) |
| Volume, $\times 10^3$ cm$^3$ | 71.1 (45.6, 96.6) | 0.79 (0.66, 0.87)     | 0.64 (0.51, 0.76)     | 0.73 (0.64, 0.83) |
| LD/APD, cm             | 2.05 (1.96, 2.13) | 0.70 (0.57, 0.80)     | 0.70 (0.57, 0.80)     | 0.72 (0.62, 0.81) |
| LD/TD, cm              | 1.67 (1.56, 1.78) | 0.73 (0.60, 0.83)     | 0.52 (0.39, 0.64)     | 0.62 (0.52, 0.73) |
| APD/TD, cm             | 0.76 (0.70, 0.81) | 0.77 (0.64, 0.86)     | 0.48 (0.36, 0.61)     | 0.63 (0.53, 0.74) |
| APD+TD, cm             | 90.5 (84.4, 96.6) | 0.66 (0.53, 0.77)     | 0.77 (0.64, 0.86)     | 0.74 (0.65, 0.83) |
| LD/(APD+TD), cm        | 0.90 (0.85, 0.96) | 0.64 (0.51, 0.76)     | 0.64 (0.51, 0.76)     | 0.68 (0.58, 0.78) |
| LD+APD, cm             | 117.5 (107.8, 127.2) | 0.70 (0.57, 0.80)     | 0.68 (0.55, 0.79)     | 0.72 (0.62, 0.82) |

Abbreviations: Est., estimated; CI, confidence interval; AUC, area under the ROC curve; LD, longitudinal diameter; APD, anteroposterior diameter; TD, transverse diameter.

Among all investigated parameters, the optimal cut-off values of APD and ratio LD/APD showed the best sensitivity and specificity. In particular, APD diameter equal or superior to 39.5 mm (95% CI, 36.2–42.8) had sensitivity of 0.70 (95% CI, 0.57–0.80), specificity of 0.71 (95% CI, 0.59–0.82) and accuracy of 0.75 (95% CI, 0.66–0.84). LD/APD ratio equal or inferior to 2.05 (95% CI, 1.96–2.13) showed sensitivity and specificity of 0.70 (95% CI, 0.57–0.80) each and accuracy of 0.72 (95% CI, 0.62–0.81).

4. Discussion

This study demonstrated that quite all biometric parameters [except for TD/(LD+APD)] at TVUS were statistically different between adenomyosis and non-adenomyosis uteri of fertile-aged women attending to tertiary referral outpatient center. Nevertheless, optimal cut-off values of these biometric parameters showed a low accuracy in diagnosing adenomyosis. Among biometric parameters, APD diameter equal or superior to 39.5 mm and LD/APD ratio equal or inferior to 2.05 showed the best combination of sensitivity and specificity.

Nowadays, TVUS performed by expert operators can be considered the first-line imaging technique to diagnose adenomyosis [10–12]. In order to standardize TVUS for diagnosing adenomyosis, MUSA consensus was proposed to detect any direct and indirect ultrasonographic features of the disease [2,26]. Myometrial cysts, hyperechogenic islands and echogenic subendometrial lines and buds are direct sonographic manifestations of the presence of ectopic endometrium in the myometrium; while indirect features, such as globular uterus, asymmetrical myometrial thickening, fan shaped shadowing, translesional vascularization and irregularity of the junctional zone, reflect myometrial hyperplasia or hypertrophy consequent to ectopic endometrial tissue implantation into the myometrium, diffuse increased myometrial vascularity and invagination of basalis endometrium in the junctional zone [27].

Among indirect feature, globular shape of the uterus showed poor pooled sensibility, moderate pooled specificity and a low accuracy in diagnosing adenomyosis using TVUS [10–12]. However, a lack of a globally accepted ultrasound description and objective biometrical characterization of the globular uterus could have contributed to its low diagnostic performance and inter-operator agreement [14,28]. In order to make a shift from a qualitative sign to a more reproducible and objective quantitative diagnostic parameter for diffuse adenomyosis, we sought to find an accurate and simple quantitative biometric uterine parameter.

According to a recent Delphi procedure, globular shape of the uterus was not defined as a merely enlargement of the uterus in size, but as a divergence of myometrial serosa of the anterior and/or posterior wall from the cervix instead of following a trajectory parallel
to the endometrium [26]. In agreement with this definition, despite we observed an increase of all three uterine diameters and organ volume, APD showed a higher increase rather than other diameters. This observation suggests the adenomyosis uteri tend to enlarge mainly in an anteroposterior direction rather than in longitudinal or transversal one.

Before our study, Mooney et al. investigated the diagnostic accuracy of the ratio between antero-posterior diameters of uterus and cervix, named myometrial-cervical ratio, in a series of pre- and post-menopausal women undergone hysterectomy for benign non obstetric conditions [19]. Despite promising results in their first retrospective study, validation prospective study on women requiring hysterectomy revealed low accuracy, sensitivity and specificity, in particular when fibroids were not excluded in the calculation of the uterine AP diameter [20].

Similarly, in our study on pre-menopausal women without diagnosis of uterine fibroid over 1 cm, despite several uterine biometric parameters and their ratios showed significant differences between adenomyosis and non-adenomyosis uteri, they presented a low diagnostic performance for diagnosing diffuse adenomyosis at TVUS. These findings may be related to high heterogeneity of the disease, which can occur with multiple sonographic and/or clinical patterns [14,27,29].

Despite prospective design and novelty of this study, it has some limitations. First, we decided to have as reference standard sonographic diagnosis by expert operators according to the presence of at least two sonographic criteria of diffuse adenomyosis, as recommended by the MUSA consensus [2,26]. Although pathological examination of the uterus is considered the gold standard, [30,31] hysterectomy is only possible in a small percentage of patients potentially affected by adenomyosis (i.e., symptomatic women with no desire of pregnancy or post-menopausal patients); moreover, no consensus about histological criteria exists. However, post-histological diagnostic era of adenomyosis has come and non-invasive methods should be clinically used to diagnose and manage fertile-age patients using a tailored approach on a case-by-case basis [4,29,32–34]. Second, the monocentric design at a tertiary referral center for endometriosis and chronic pelvic pain potentially limits the generalization of our findings. However, we selected uterine biometric parameters according to the MUSA consensus which are easily reproducible. Third, small sample size may limit the reliability of our results. Nevertheless, we adopted strict inclusion/exclusion criteria for avoiding confounding factors on uterine diameters.

Further larger studies are needed to confirm our data and investigate the role of sonographic biometric parameters of the uterus in diagnosing of adenomyosis in different settings and conditions.

5. Conclusions

Although several biometric uterine parameters at TVUS in fertile-aged women were statistically different between adenomyosis and non-adenomyosis uteri, their optimal cutoff values showed low accuracy in diagnosing adenomyosis, potentially limiting their application in the clinical practice.

Future larger studies are needed to further evaluate their usefulness as diagnostic markers of diffuse adenomyosis.

Author Contributions: Conceptualization, P.C., E.Z., A.R. and D.R.; methodology, M.G., L.L., B.O., L.D.M., E.Z., R.S. and P.C.; software, J.L. and M.G.; validation, L.L., A.M. and A.T.; formal analysis, J.L.; investigation, B.O., L.V. and L.L.; resources, A.M. and A.T.; data curation, B.O., L.V. and L.D.M.; writing—original draft preparation, D.R., A.R. and M.G.; writing—review and editing, D.R., L.L. and P.C.; visualization, M.G., D.R. and A.R.; supervision, E.Z., P.C. and R.S.; project administration, A.M. and A.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.
I nstitutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the local Ethics Committee of Azienda Ospedaliero-Universitaria di Bologna (protocol code 114/2022/Oss/AOUBo and date of approval 24 March 2022).

Informed Consent Statement: Written informed consent has been obtained from the patients to publish this paper.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to the need of privacy maintenance of patients.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Cunningham, R.K.; Horrow, M.M.; Smith, R.J.; Springer, J. Adenomyosis: A Sonographic Diagnosis. RadioGraphics 2018, 38, 1576–1589. [CrossRef] [PubMed]
2. van den Bosch, T.; Dueholm, M.; Leone, F.P.G.; Valentin, L.; Rasmussen, C.K.; Votino, A.; Van Schoubroeck, D.; Landolfo, C.; Installé, A.J.; Guerriero, S.; et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: A consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet. Gynecol. 2015, 46, 284–298. [CrossRef] [PubMed]
3. Van den Bosch, T.; de Bruijn, A.M.; de Leeuw, R.A.; Dueholm, M.; Exacoustos, C.; Valentin, L.; Bourne, T.; Timmerman, D.; Huirne, J.A.F. Sonographic classification and reporting system for diagnosing adenomyosis. Ultrasound Obstet. Gynecol. 2019, 53, 576–582. [CrossRef] [PubMed]
4. Exacoustos, C.; Morosetti, G.; Conway, F.; Camilli, S.; Martire, F.G.; Lazzeri, L.; Piccione, E.; Zupi, E. New Sonographic Classification of Adenomyosis: Do Type and Degree of Adenomyosis Correlate to Severity of Symptoms? J. Minim. Invasive Gynecol. 2020, 27, 1308–1315. [CrossRef] [PubMed]
5. Harada, T.; Khine, Y.M.; Kaponis, A.; Nikellis, T.; Decavalas, G.; Taniguchi, F. The Impact of Adenomyosis on Women’s Fertility. Obstet. Gynecol. Survey. 2016, 71, 557–568. [CrossRef] [PubMed]
6. di Donato, N.; Montanari, G.; Benfenati, A.; Leonardi, D.; Bertoldo, V.; Monti, G.; Raimondo, D.; Seracchioli, R. Prevalence of adenomyosis in women undergoing surgery for endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014, 181, 289–293. [CrossRef] [PubMed]
7. Raffone, A.; Seracchioli, R.; Raimondo, D.; Maletta, M.; Travaglino, A.; Raimondo, I.; Giaquinto, I.; Orsini, B.; Insabato, L.; Pellicano, M.; et al. Prevalence of adenomyosis in endometrial cancer patients: A systematic review and meta-analysis. Arch. Gynecol. Obstet. 2021, 303, 47–53. [CrossRef] [PubMed]
8. Mabrouk, M.; Raimondo, D.; Mastronardi, M.; Raimondo, I.; Del Forno, S.; Arena, A.; Sutherland, N.; Borgia, A.; Mattioli, G.; Terzano, P.; et al. Endometriosis of the Appendix: When to Predict and How to Manage—A Multivariate Analysis of 1935 Endometriosis Cases. J. Minim. Invasive Gynecol. 2020, 27, 100–106. [CrossRef]
9. Naftalin, J.; Hoo, W.; Pateman, K.; Mavrelos, D.; Holland, T.; Jurkovic, D. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum. Reprod. 2012, 27, 3432–3439. [CrossRef] [PubMed]
10. Andres, M.P.; Borrelli, G.M.; Ribeiro, J.; Baracat, E.C.; Abrão, M.S.; Kho, R.M. Transvaginal Ultrasound for the Diagnosis of Adenomyosis: Systematic Review and Meta-Analysis. J. Minim. Invasive Gynecol. 2018, 25, 257–264. [CrossRef] [PubMed]
11. Tellum, T.; Nygaard, S.; Lieng, M. Noninvasive Diagnosis of Adenomyosis: A Structured Review and Meta-analysis of Diagnostic Accuracy in Imaging. J. Minim. Invasive Gynecol. 2020, 27, 408–418. [CrossRef] [PubMed]
12. Liu, L.; Li, W.; Leonardi, M.; Cordous, F.; Da Silva Costa, F.; Mol, B.W.; Wong, L. Diagnostic Accuracy of Transvaginal Ultrasound and Magnetic Resonance Imaging for Adenomyosis. J. Ultrasound Med. 2021, 40, 2289–2306. [CrossRef] [PubMed]
13. Bromley, B.; Shipp, T.D.; Benacerraf, B. Adenomyosis: Sonographic findings and diagnostic accuracy. J. Ultrasound Med. 2000, 19, 529–534. [CrossRef] [PubMed]
14. Lazzeri, L.; Morosetti, G.; Centini, G.; Monti, G.; Zupi, E.; Piccione, E.; Exacoustos, C. A sonographic classification of adenomyosis: Interobserver reproducibility in the evaluation of type and degree of the myometrial involvement. Fertil. Steril. 2018, 110, 1154–1161. [CrossRef]
15. da Silva, J.R.; Andres, M.P.; Leite, A.P.K.; Gomes, M.T.N.A.; Neto, J.S.; Baracat, E.C.; Carmona, F.; Abrão, M.S. Comparison of Sensitivity and Specificity of Structured and Narrative Reports of Transvaginal Ultrasoundography for Adenomyosis. J. Min-im. Invasive Gynecol. 2021, 28, 1216–1224. [CrossRef] [PubMed]
16. Kepkep, K.; Tuncay, Y.A.; Gönynüler, G.; Tural, E. Transvaginal sonography in the diagnosis of adenomyosis: Which findings are most accurate? Ultrasound Obstet. Gynecol. 2007, 30, 341–345. [CrossRef] [PubMed]
17. Sun, Y.L.; Wang, C.B.; Lee, C.Y.; Wun, T.H.; Lin, P.; Lin, Y.H.; Tseng, C.C.; Chen, C.H.; Tseng, C.J. Transvaginal Sonographic Criteria for the Diagnosis of Adenomyosis Based on Histopathologic Analysis. Taiwan J. Obstet. Gynecol. 2010, 49, 40–44. [CrossRef] [PubMed]
18. Zannoni, L.; Ambrosio, M.; Raimondo, D.; Arena, A.; Del Forno, S.; Borghese, G.; Paradisi, R.; Seracchioli, R. Question Mark Sign and Transvaginal Ultrasound Uterine Tenderness for the Diagnosis of Adenomyosis. *J. Ultrasound Med.* 2020, 39, 1405–1412. [CrossRef] [PubMed]

19. Mooney, S.; Roberts, R.; McGinnes, D.; Ellett, L.; Maher, P.; Ireland-Jenkin, K.; Stone, K. The myometrial-cervical ratio (MCR): Assessing the diagnostic accuracy of a novel ultrasound measurement in the diagnosis of adenomyosis. *Aust. N. Z. J. Obstet. Gynaecol.* 2022, 62, 110–117. [CrossRef]

20. McCaughey, T.; Mooney, S.; Harlow, K.; Healey, M.; Stone, K. The use of the myometrial-cervical ratio in the ultrasound diagnosis of adenomyosis—A validation study. *Aust. N. Z. J. Obstet. Gynaecol.* 2022, 62, 560–565. [CrossRef] [PubMed]

21. von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. *Ann. Intern. Med.* 2007, 147, 573–577, Erratum in *Ann. Intern. Med.* 2008, 148, 168. [CrossRef]

22. Exacoustos, C.; Brienza, L.; Di Giovanni, A.; Szabolcs, B.; Romanini, M.E.; Zupi, E.; Arduini, D. Adenomyosis: Three-dimensional sonographic findings of the junctional zone and correlation with histology. *Ultrasound Obstet. Gynecol.* 2011, 37, 471–479. [CrossRef] [PubMed]

23. di Donato, N.; Bertoldo, V.; Montanari, G.; Zannoni, L.; Caprara, G.; Seracchioli, R. Question mark form of uterus: A simple sonographic sign associated with the presence of adenomyosis. *Ultrasound Obstet. Gynecol.* 2015, 46, 126–127. [CrossRef]

24. Bluhm, M.; Dueholm, M. Imaging for Adenomyosis: Making the Diagnosis by Sonography. *J. Minim. Invasive Gynecol.* 2020, 27, 267. [CrossRef] [PubMed]

25. Raimondo, D.; Raffone, A.; Aru, A.C.; Salucci, P.; Travaglino, A.; Maletta, M.; Ambrosio, M.; Borghese, G.; Iodice, R.; Casa-dio, P.; et al. C-reactive Protein for Predicting Early Postoperative Complications in Patients Undergoing Laparoscopic Shav-ing for Deep Infiltrating Endometriosis. *J. Minim. Invasive Gynecol.* 2022, 29, 135–143. [CrossRef] [PubMed]

26. Harmsen, M.J.; Van den Bosch, T.; de Leeuw, R.A.; Dueholm, M.; Exacoustos, C.; Valentin, L.; Hehenkamp, W.J.K.; Groen-man, F.; De Bruyn, C.; Rasmussen, C.; et al. Consensus on revised definitions of Morphological Uterus Sonographic Assess-ment (MUSA) features of adenomyosis: Results of modified Delphi procedure. *Ultrasound Obstet. Gynecol.* 2022, 60, 118–131. [CrossRef]

27. Ferenczy, A. Pathophysiology of adenomyosis. *Hum. Reprod. Update* 1998, 4, 312–322. [CrossRef] [PubMed]

28. Rasmussen, C.K.; Van den Bosch, T.; Exacoustos, C.; Manegold-Brauer, G.; Benacerraf, B.R.; Froyman, W.; Landolfo, C.; Condorelli, M.; Eggekvist, A.G.; Josefsson, H.; et al. Intra- and Inter-Rater Agreement Describing Myometrial Lesions Using Morphologic Uterus Sonographic Assessment: A Pilot Study. *J. Ultrasound Med.* 2019, 38, 2673–2683. [CrossRef] [PubMed]

29. Struble, J.; Reid, S.; Bedaiwy, M.A. Adenomyosis: A Clinical Review of a Challenging Gynecologic Condition. *J. Minim. Invasive Gynecol.* 2016, 23, 164–185. [CrossRef] [PubMed]

30. Levgur, M.; Abadi, M.A.; Tucker, A. Adenomyosis: Symptoms, histology, and pregnancy terminations. *Obstet. Gynecol.* 2000, 95, 688–691. [CrossRef] [PubMed]

31. Bergholt, T.; Eriksen, L.; Berendt, N.; Jacobsen, M.; Hertz, J.B. Prevalence and risk factors of adenomyosis at hysterectomy. *Hum. Reprod.* 2001, 16, 2418–2421. [CrossRef] [PubMed]

32. Zannoni, L.; Del Forno, S.; Raimondo, D.; Arena, A.; Giaquinto, I.; Paradisi, R.; Casadio, P.; Meriggiola, M.C.; Seracchioli, R. Adenomyosis and endometriosis in adolescent and young women with pelvic pain: Prevalence and risk factors. *Minerva Pediatr.* 2020, online ahead of print. [CrossRef]

33. Exacoustos, C.; Zupi, E. A new era in diagnosing adenomyosis is coming. *Fertil. Steril.* 2018, 110, 858. [CrossRef] [PubMed]

34. Chen, Q.; Li, Y.W.; Wang, S.; Fan, Q.B.; Shi, H.H.; Leng, J.H.; Sun, D.W.; Lang, J.H.; Zhu, L. Clinical Manifestations of Ade-nomyosis Patients with or Without Pain Symptoms. *J. Pain Res.* 2019, 12, 3127–3133. [CrossRef] [PubMed]